Back to search results

Betamethasone for Extremely Premature Babies

This study is looking at whether a steroid medication called betamethasone, given after birth, can help extremely premature babies (born before 28 weeks) come off breathing machines more easily and reduce their risk of chronic lung disease (bronchopulmonary dysplasia). Only babies who meet specific criteria for severe lung disease will receive betamethasone. The study aims to see if betamethasone helps babies get off breathing support and if it causes any harmful side effects on their growth or development. All babies in the study will receive standard care and have their progress, growth, and development tracked over time. The study plans to enroll 100 infants, but its current status is unclear.

Study design
This is an interventional study with a planned enrollment of 100 infants. Babies with severe lung disease will receive betamethasone, while those without will not.
What's involved
Infants who receive betamethasone will get a 5-day course of injections. All babies will have their progress, growth, and development followed over time.
Compensation
Not stated in the trial record.
Follow-up
The study will measure successful breathing support removal from the start of treatment until 7 days after treatment ends. Growth and development will be followed over time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07447739

Can Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively?

Not Yet Recruiting
PHASE2Up to 28InterventionalTreatment
Khang Nguyen
~100 participants
Updated 2026-03-03 on ClinicalTrials.gov
What's tested:Betamethasone

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The rate of successful respiratory weaning
Measured over From initiation of treatment until 7 days after treatment completion

Conditions

Respiratory Distress Syndrome (RDS)
Bronchopulmonary Dysplasia (BPD)

Explore related trials

Bronchopulmonary DysplasiaExtremely Low Gestational Age NeonatesRespiratory Distress Syndrome

NCT07447739

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Maria Fareri Children's Hospital at Westchester Medical Center

    Valhalla, New Yorkstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jordan Kase, MD · PRINCIPAL_INVESTIGATOR · Maria Fareri Children's Hospital

Who to contact

Jordan Kase, MD
[email protected]
914-493-8558
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Infants born at less than 28 weeks gestation age
Admitted to WMC NICU prior to day of life 35

Exclusion

Infants with major congenital or chromosomal abnormalities.
Death prior to DOL 8.
Previous exposure to postnatal steroids

What this trial measures

  • The rate of successful respiratory weaningFrom initiation of treatment until 7 days after treatment completion

    * Defined by a 20% reduction from baseline in mean airway pressure or FiO2 if patient remains intubated * or successful extubation and maintenance of extubation for 7 days after betamethasone completion